MediciTx

Medici Therapeutics is a biotechnology company focused on developing next-generation cancer immunotherapies by leveraging novel insights into the tumor microenvironment and immune evasion. Formed through a collaboration between ARCH Venture Partners and the Parker Institute for Cancer Immunotherapy (PICI), the company integrates programs from Marble Therapeutics and Nutcracker Therapeutics. Medici's primary focus is on advancing tumor-infiltrating lymphocyte (TIL) therapies, specifically by infusing TILs with healthy mitochondria to enhance their anti-tumor functionality and durability. Additionally, the company utilizes an in-house mRNA manufacturing platform to develop personalized cancer vaccines and other RNA-based medicines. Led by industry veterans like Dr. Ira Mellman and Dr. Nicholas Restifo, Medici Therapeutics aims to overcome resistance to current immunotherapies and deliver transformative treatments for patients with stubborn cancers.